Offspring may inherit legacy of their father’s Toxoplasma infection
29 April 2020 Melbourne researchers at the Walter and Eliza Hall Institute have revealed for the first time that males infected with the Toxoplasma parasite can impact their offspring’s brain health and behaviour. Studying mice infected with the common parasite Toxoplasma,…
Cracking the COVID-19 immunity code
29 April 2020 Monash University’s Dr James McMahon, an infectious disease expert and hospital clinician at The Alfred and Monash Health, is leading the development of a biobank aimed at cracking the immunity code of COVID-19. The biobank enables…
Immutep Reports Positive Phase II TACTI-002 Data
28 April 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces further positive interim data from its ongoing Phase II TACTI-002 study. The data relates to the…
New type of immune cell discovered in breast ducts
28 April 2020 Melbourne breast cancer researchers have discovered a new type of immune cell that helps to keep breast tissue healthy by regulating a vital process within mammary ducts – the sites where milk is produced and…
Researchers create world’s first ultrasound biosensor
23 April 2020 Australian researchers have made a world-first breakthrough that has the potential to monitor the changes in pH levels and other responses to therapy in stroke and cancer patients. Researchers from Monash University and the Baker…
Trials begin for a new type of face mask
22 April 2020 RMIT fashion and textiles experts have designed a new style of protective face mask for healthcare workers. The staff and student team has sewn 100 of the prototype masks as part of a Federal Government…
Immutep completes enrollment for INSIGHT-004 study
23 April 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004 Phase I clinical…
PolyNovo first Canadian BTM use
23 April 2020 PolyNovo is pleased to announce the first use of NovoSorb BTM in Canada. This case was initiated by one of Canada’s leading surgeons who is a key opinion leader in this field. PolyNovo has not…
NovoSorb® BTM Feasibility Study Results for US FDA
21 April 2020 PolyNovo is pleased to share the summary of results for the CP-002 Feasibility Study to assess the safety and effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the treatment of severe skin burn injuries. This…
VivaZome Therapeutics Pty Ltd and ToolGen, Inc. extend collaboration agreement based on successful proof-of-concept outcomes
22 April 2020 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the extension of a collaborative research project exploring the gene-editing of cells for enhanced exosome production. Under the…
Bosch Australia’s Manufacturing Solutions business unit awarded COVID-19 project by Grey Innovation
21 April 2020 Bosch Australia’s Manufacturing Solutions division (BAMS) has been awarded a AUD $1 million project as part of the industry consortium to build ventilators in Victoria. The notus Emergency Invasive Ventilator Program, a Grey Innovation led…
Victoria’s coronavirus (COVID-19) modelling confirms staying at home saves lives
20 April 2020 The Victorian Government has released modelling to provide greater understanding of the spread of coronavirus in Victoria. The modelling, done by Victoria’s epidemiological experts at the Department of Health and Human Services and in collaboration…
